Malaga Cove Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Malaga Cove Capital’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-56,993	Closed	-$617K	–	174
2018 Q3	$617K	Sell	56,993 -654	-1%	-$7.49K	0.34%	89
2018 Q2	$692K	Sell	57,647 -2,054	-3%	-$21K	0.35%	92
2018 Q1	$512K	Buy	59,701 +314	+0.5%	+$2.9K	0.28%	95
2017 Q4	$587K	Buy	59,387 +16,198	+38%	+$168K	0.33%	85
2017 Q3	$521K	Buy	+43,189	New	+$638K	0.3%	87

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

SGA

Sector Gamma AS Oslo, Norway $461M AUM 33.26% 1-Year Est. Return

Malaga Cove Capital's LXRX Position: Q4 2018 in Review

Malaga Cove Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2018, closing a stake of 56,993 shares — an estimated $617K sold.

Malaga Cove Capital first reported a position in LXRX in Q3 2017 and held it in 5 quarters. The position peaked at $692K in Q2 2018. 122 funds tracked by Wall St. Rank hold LXRX as of Q4 2018.

Malaga Cove Capital reported no remaining Lexicon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Malaga Cove Capital sold 56,993 Lexicon Pharmaceuticals shares in Q4 2018, an estimated $617K.
Malaga Cove Capital first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Malaga Cove Capital's Lexicon Pharmaceuticals position peaked at $692K in Q2 2018.
122 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2018.

Based on Malaga Cove Capital's 13F filing for Q4 2018, filed 4 Feb 2019.